MAPT and early-onset autosomal dominant Alzheimer disease: While it activates PKA and increases tau phosphorylation at several sites associated with Alzheimer’s disease, this priming makes tau more susceptible to further phosphorylation by glycogen synthase kinase-3 (GSK-3), suggesting both beneficial and potentially detrimental effects in Alzheimer’s pathology [142,143].